



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	HLM30 Cells
Catalog Number:	2091
Lot Number:	4/11/94
Release Category:	C
Provided:	6 x 10 ⁶ cells/vial.
Cell Type:	HeLa CD4+ cells (Catalog #154 from Dr. Richard Axel), were transduced with the <i>tat</i> -defective mutant pMtat30 (Catalog #2087), which contains a TGT→GGT substitution at cysteine residue 30 in the <i>tat</i> reading frame. The HIV proviral DNA was derived from pHXB2gpt, an infectious molecular clone of HIV-1 IIIIB (Catalog #398, from Dr. R. Gallo).
Propagation Medium:	MEM, 95%; horse serum, 5%; 10 µg/ml gentamicin. These cells can be adapted for growth in richer media and in fetal bovine serum; however, maintaining them in MEM with 5% horse serum is less likely to cause the cells to spontaneously produce background virus.
Freeze Medium:	MEM, 70%; horse serum, 20%; DMSO, 10%.
Growth Characteristics:	These cells can be maintained in culture by adding fresh medium to the adherent cells every 3-4 days. Trypsinization is necessary only once every month or so unless the cells become overconfluent or need to be transferred to an additional flask.
Sterility:	Negative for bacteria, fungi, and mycoplasma.
Description:	HLM30 cells are CD4+ and negative for virus particle production, but can be stimulated to produce non-infectious virions.
Special Characteristics:	HLM30 cells are negative for virus particle production, but will produce HIV-1 after cocultivation with <i>tat</i> -expressing cells, or after exposure to UV light and subsequent coculture with H9 cells. The resultant virus is a mixture of infectious revertants and defective HIV-1 mutants.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Contributor: Dr. Reza Sadaie.

References: Sadaie MR, Tschachler E, Valerie K, Rosenberg M, Felber BK, Pavlakis GN, Klotman ME, Wong-Staal F. Activation of *tat*-defective human immunodeficiency virus by ultraviolet light. *New Biol* **2**:479-486, 1990.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HLM30 Cells from Dr. Reza Sadaie." Also include the reference cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact FDA Invention Licensing at the following email address: FDAINventionLicensing@fda.hhs.gov, before the reagent can be released.

Last Updated September 16, 2019

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.